lunes, 23 de febrero de 2026
Gilead to buy Arcellx in nearly $8B deal The two companies were already partnered on a multiple myeloma CAR-T treatment
https://www.statnews.com/2026/02/23/gilead-arcellx-acquisition-car-t-multiple-myeloma/
By Adam FeuersteinFeb. 23, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario